肾酶与心血管疾病

Renalase and Cardiovascular Diseases

肾酶是一种主要由肾脏分泌的新型黄素腺嘌呤二核苷酸依赖的胺氧化酶,能降解循环中的儿茶酚胺,调节心功能和血压。慢性肾脏疾病和终末期肾病患者血浆肾酶显著降低,其心血管疾病并发症明显增加;肾酶基因多态性与原发性高血压发病易感性增加相关;外源性肾酶能够显著降低大鼠的心肌梗死面积、心率、外周血管阻力和平均动脉压,调节心肌收缩性,改善左心室功能,提示肾酶与心血管疾病密切相关,可能具有良好的生理、病理和药理学应用前景。

Renalase is a novel flavin adenine dinucleotide-dependent amine oxidase secreted by the kidney, which degrades circulating catecholamines and modulates cardiac function and systemic blood pressure. The plasma concentration of renalase is markedly reduced in patients with chronic kidney disease and end-stage renal disease, who have a marked increase in cardiovascular morbidity and mortality. The gene polymorphism of renalase is associated with the increase of the susceptibility for essential hypertension. Renalase infusion in rats can remarkably reduce the infarct size, heart rate, peripheral vascular resistance and mean artery blood pressure, and improve left ventricular function through regulating cardiac contractility in rats with acute myocardial infarction. It is suggested that renalase plays a key role in the regulation of sympathetic tone, blood pressure and cardiac function.